PROGRAM and ABSTRACTS

Second International Conference on Malignant Lymphoma

June, 13-16, 1984
Lugano, Switzerland

ORGANIZING COMMITTEE:
F. Cavalli (Bellinzona),
G. Bonadonna (Milan),
M. Rozencweig (Syracuse)

ADVISORY BOARD:
C. Berard (Memphis),
R.C. Young (Bethesda),
S. Rosenberg, (Stanford),
H. Rappaport (Duarte),
J.E. Ultmann (Chicago)

Sponsored by The Swiss League Against Cancer, La Lega Ticinese Contro il Cancro, and Swiss Group for Clinical Cancer Research (SAKK).
# CONFERENCE SCHEDULE

**WEDNESDAY, June 13, 1984**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 - 5:00 p.m.</td>
<td>SATELLITE SYMPOSIUM (Room A)</td>
</tr>
<tr>
<td></td>
<td>INTERFERON ALPHA 2 - PRECLINICAL AND CLINICAL EVALUATION</td>
</tr>
<tr>
<td>5:00 - 7:00 p.m.</td>
<td>WELCOME PARTY (Room B)</td>
</tr>
<tr>
<td>7:30 - 10:00 p.m.</td>
<td>Session 1 - INTRODUCTORY LECTURES (Room A)</td>
</tr>
</tbody>
</table>

**THURSDAY, June 14, 1984**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 - 9:45 a.m.</td>
<td>Session 2 - MONOCLONAL ANTIBODIES: CLINICAL AND RESEARCH ASPECTS (Room A)</td>
</tr>
<tr>
<td>10:05 - 12:00 a.m.</td>
<td>Session 3 - IMMUNOLOGY (Room A)</td>
</tr>
<tr>
<td>1:45 - 3:30 p.m.</td>
<td>Session 4 - HODGKIN'S DISEASE: OVERVIEW (Room A)</td>
</tr>
<tr>
<td>3:50 - 6:00 p.m.</td>
<td>Session 5 - (first part) HODGKIN'S DISEASE IN ADULTS (Room A)</td>
</tr>
<tr>
<td>3:45 - 6:00 p.m.</td>
<td>Session 6 - LYMPHOMA IN CHILDREN (Room B)</td>
</tr>
<tr>
<td>2:00 - 6:00 p.m.</td>
<td>Session 7 - WORKSHOP ON ENZYMATIC PATHWAYS IN NORMAL AND PATHOLOGICAL LYMPHOID CELLS (Room C)</td>
</tr>
<tr>
<td>7:30 - 10:00 p.m.</td>
<td>Session 8 - WORKSHOP ON CYTOGENETICS OF HUMAN MALIGNANT LYMPHOMA (Room B)</td>
</tr>
<tr>
<td>7:30 - 9:30 p.m.</td>
<td>Session 5 - HODGKIN'S DISEASE IN ADULTS (Room A) (continuation)</td>
</tr>
</tbody>
</table>

**FRIDAY, June 15, 1984**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 - 10:00 a.m.</td>
<td>POSTER SESSION (Villa Ciani)</td>
</tr>
<tr>
<td>10:00 - 12:00 a.m.</td>
<td>Session 9 - SPECIAL FEATURES OF MALIGNANT LYMPHOMA (Room A)</td>
</tr>
<tr>
<td>1:45 - 3:20 p.m.</td>
<td>Session 10 - NON-HODGKIN LYMPHOMA: OVERVIEW (Room A)</td>
</tr>
<tr>
<td>3:30 - 6:00 p.m.</td>
<td>Session 11 - PATHOLOGY (Room B)</td>
</tr>
<tr>
<td>3:30 - 5:45 p.m.</td>
<td>Session 12 - TREATMENT OF NON-HODGKIN LYMPHOMA IN ADULTS (Room A)</td>
</tr>
<tr>
<td>8:30 p.m.</td>
<td>&quot;MUMMENSCHANZ&quot; (Room A)</td>
</tr>
</tbody>
</table>

**SATURDAY, June 16, 1984**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 - 10:45 a.m.</td>
<td>Session 13 - BONE MARROW TRANSPLANTATION IN NON HODGKIN LYMPHOMA (Room A)</td>
</tr>
<tr>
<td>8:30 - 10:45 a.m.</td>
<td>Session 14 - NON HODGKIN LYMPHOMA: CLINICAL-PATHOLOGICAL CORRELATIONS (Room B)</td>
</tr>
<tr>
<td>11:00 a.m.</td>
<td>HENRY KAPLAN MEMORIAL LECTURE (Room A)</td>
</tr>
<tr>
<td>12:00 a.m.</td>
<td>ADJOURN</td>
</tr>
</tbody>
</table>
POSTER SESSION
Localisation of posters

VILLA CIANI

PALAZZO DEI CONGRESSI
BRISTOL Cytostatics

Worldwide Recognized
Antitumor Agents

BiCNU (Carmustine/BCNU)

CiNU (Lomustine/CCNU)

LYSODREN (Mitotane o,p'-DDD)

MEGESTAT (Megestrol Acetate)

MEXATE (Methotrexate)

MUTAMYCIN (Mitomycin C)

PLATINOL (Cisplatin/DDP)

VEPESID (Etoposide/VP-16)

VUMON (Teniposide/VM-26)

m-AMSA (Amsacrine)

Medical Information & distribution
Bristol Myers SA  Riedstrasse 3
6330 Cham  042 / 38 13 13
Switzerland

BRISTOL
### Conference Schedule

**Wednesday, June 13, 1984**
7:30 - 10:00 p.m.

**Session 1 - Introductory Lectures (Room A)**
Chairman: F. Cavalli

<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract</th>
<th>Title, Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 p.m.</td>
<td></td>
<td>WELCOME AND INTRODUCTORY REMARKS. F. Cavalli</td>
</tr>
<tr>
<td>7:45</td>
<td>1</td>
<td>CURRENT THOUGHTS CONCERNING ONCOGENS IN HUMAN NEOPLASIAS. G.M. Cooper, Boston, USA</td>
</tr>
<tr>
<td>8:30</td>
<td>2</td>
<td>POTENTIAL OF MONOCLONAL ANTIBODIES IN ONCOLOGY. J.-C. Cerottini, Lausanne, Switzerland</td>
</tr>
<tr>
<td>9:15</td>
<td>3</td>
<td>OVERVIEW ON CURRENT TOPICS IN CLINICAL RESEARCH. S. Rosenberg, Stanford, USA</td>
</tr>
</tbody>
</table>

**Thursday, June 14, 1984**
8:00 - 9:45 a.m.

**Session 2 - Monoclonal Antibodies: Clinical and Research Aspects (Room A)**
Chairmen: R. Levy and S. Schlossman

<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract</th>
<th>Title, Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m.</td>
<td>4</td>
<td>HODGKIN’S DISEASE: FURTHER INFORMATION DERIVED FROM CELL-LINES. V. Diehl, Köln, West-Germany</td>
</tr>
<tr>
<td>8:20</td>
<td>5</td>
<td>ORIGIN AND BIOLOGIC FUNCTION OF REED-STERNBERG CELLS. R.i. Fisher, Bethesda, USA</td>
</tr>
<tr>
<td>8:45</td>
<td>6</td>
<td>RADIOIMMUNODETECTION OF HUMAN B-CELL LYMPHOMAS WITH A RADIOLABELED TUMOR-SPECIFIC MONOCLONAL ANTIBODY (Lym-1). A.L. Epstein, et al, Chicago, USA</td>
</tr>
<tr>
<td>9:00</td>
<td>7</td>
<td>THERAPEUTIC USE OF MONOCLONAL ANTI-IDIOTYPE ANTIBodies AGAINST B-CELL LYMPHOMA. A.Hekman, et al, Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>9:15</td>
<td>8</td>
<td>THE IMMUNOBIOLOGY OF B-CELL LYMPHOMA. R. Levy, Stanford, USA</td>
</tr>
<tr>
<td>9:45</td>
<td></td>
<td>INTERMISSION</td>
</tr>
</tbody>
</table>
Thursday, June 14, 1984
10:05 - 12:00 a.m.

Session 3 - IMMUNOLOGY (Room A)
Chairmen: J.-C. Cerottini and K. Lennert

10:05 a.m. 9  T-CELL DIFFERENTIATION: IMPLICATIONS FOR THE ONCOLOGIST AND BIOLOGIST. S.F. Schlossman, Boston, USA

10:35 10  IMMUNOLOGIC PHENOTYPES OF NON-HODGKIN'S LYMPHOMAS: CORRELATION WITH MORPHOLOGY AND FUNCTION. E.S. Jaffe, Bethesda, USA

11:05 11  FUNCTIONAL INTERACTIONS OF MALIGNANT CELLS DURING B CELL LYMPHOMA GENESIS. C.L. Reinisch, Boston, USA

11:15 12  BLOOD LYMPHOCYTE SUBPOPULATIONS AND MITOGEN RESPONSIVENESS IN RELATION TO PROGNOSIS IN PATIENTS WITH NON-HODGKIN LYMPHOMA. Ch. Lindemalm, et al, Stockholm, Sweden

11:25 13  CELLULAR INTERACTIONS REGULATING T-CELL COLONY FORMATION IN THE ABSENCE OF ADDED GROWTH FACTORS IN PATIENTS WITH T-CELL MALIGNANCIES. V. Georgoulis, et al, Paris, France


11:45 66  NON-HODGKIN'S LYMPHOMAS IN HOMOSEXUAL MALES. S. Riggs, et al, Houston, USA

12:00  LUNCH (Room B)

Session 4 - HODGKIN'S DISEASE: OVERVIEW (Room A)
Chairman: M. Peckham

1:45 - 3:30 p.m.

1:45 p.m. 16  THE CURRENT STATUS OF NCI TRIALS IN HODGKIN'S DISEASE. R.C. Young, Bethesda, USA

2:05 17  THE CURRENT STATUS OF STANFORD HODGKIN'S DISEASE TRIALS. S.A. Rosenberg, Stanford, USA

2:25 18  ALTERNATING CHEMOTHERAPY WITH MOPP/ABVD IN HODGKIN'S DISEASE: UPDATED RESULTS. G. Bonadonna, Milan, Italy

2:45 19  COMBINED MODALITY THERAPY FOR HODGKIN'S DISEASE. E. Glatstein, Bethesda, USA
CURRENT STATUS OF THE CURABILITY OF CHILDREN WITH HODGKIN'S DISEASE (HD): AN ASSESSMENT OF THE RISK: BENEFIT RATIO OF MODERN THERAPY. S.B. Murphy, Memphis, USA

DISCUSSION

INTERMISSION

Session 5 (first part)
HODGKIN'S DISEASE IN ADULTS (Room A)
Chairmen: R.C. Young and H.P. Honegger

LATE EFFECTS OF CHEMOTHERAPY IN HODGKIN'S DISEASE. T.A. Lister, London, England

SECONDARY ACUTE NONLYMPHOCYTIC LEUKEMIA (ANLL) AND DYSMYELOPOIETIC SYNDROME (DMPS): A MODEL OF LEUKEMOGENESIS WITH IMPLICATIONS IN THE PRIMARY TREATMENT OF LYMPHOMAS. J.E. Ultmann, Chicago, USA

SECOND CANCERS AFTER TREATMENT IN TWO SUCCESSIVE COHORTS OF PATIENTS WITH EARLY STAGES OF HODGKIN'S DISEASE. M. Henry-Amar, et al, Villejuif, France

LACK OF CORRELATION OF ANN ARBOR CLINICAL PARAMETERS AND BIOPSY DETERMINATION OF LIVER INVOLVEMENT IN STAGE III AND IV HODGKIN'S DISEASE: A SOUTHWEST ONCOLOGY GROUP (SWOG) STUDY. C.J. Fabian, et al, Kansas City, USA

LONG TERM FOLLOW-UP OF PATIENTS WITH CLINICAL STAGES I, II HODGKIN'S DISEASE: COMPARISON OF INITIAL SPLENECTOMY AND SPLEEN IRRADIATION. M. Hayat, et al, Villejuif, France

STAGING LAPAROTOMY WITH SPLENECTOMY IN STAGE 1 AND II HODGKIN'S DISEASE: NO THERAPEUTIC BENEFIT. G.A. Gomez, et al, Buffalo, USA

SURGICAL RESTAGING AFTER 3 OR 6 COURSES OF MOPP CHEMOTHERAPY IN HODGKIN'S DISEASE (HD). UPDATED RESULTS. C. Ferme, et al, Briis Sous Forges, France

Session 6 - LYMPHOMA IN CHILDREN (Room B)
Chairpersons: S. Murphy and H.J. Riehm

3:45 p.m.  29  STRATEGIES FOR MANAGEMENT OF CHILDHOOD NON-HODGKIN’S LYMPHOMAS (NHL) BASED UPON STAGE AND IMMUNOPATHOLOGIC SUBTYPE: RATIONALE AND CURRENT RESULTS. S.B. Murphy, Memphis, USA

4:00  30  RESULTS OF THE BFM THERAPY FOR CHILDHOOD NON-HODGKIN’S LYMPHOMA. IMPROVEMENT OF PROGNOSIS BY ADAPTATION OF CHEMOTHERAPY TO STAGE AND TYPE. St. Müller-Weihrich, München, West-Germany


4:25  32  THERAPY OF UNDIFFERENTIATED (INCLUDING BURKITT’S) AND LYMPHOBLASTIC LYMPHOMAS IN CHILDREN AND YOUNG ADULTS. I.T. Magrath, Bethesda, USA

4:40  33  EVOLUTION OF THE THERAPEUTIC APPROACHES OF NON-HODGKIN'S LYMPHOMA OF CHILDHOOD. C. Jacquillat, Paris, France

4:50  34  CHILDHOOD HODGKIN'S DISEASE: TREATMENT WITH ABVD CHEMOTHERAPY AND LIMITED FIELD RADIOTHERAPY. F. Fossati, Milan, Italy

5:05  35  COMBINED TREATMENT MODALITY WITH REDUCED CHEMO- AND RADIOTHERAPY IN HODGKIN'S DISEASE: RESULTS FROM 300 CHILDREN IN 2 CONSECUTIVE STUDIES. G. Schellong, et al, Münster, West-Germany

5:20  36  HODGKIN'S DISEASE (HD) IN CHILDHOOD: TREATMENT WITH CHEMOTHERAPY AND LOW-DOSE RADIATION. RATIONALE AND FEASIBILITY. O. Oberlin, et al, Villejuif, France

5:30  37  HODGKIN'S DISEASE (HD) IN CHILDHOOD AND ADOLESCENCE. RESULTS OF CHEMOTHERAPY-RADIOThERAPY (CT-RT) IN CLINICAL STAGES (CS) IA-IIa. Ph. Cramer, et al, Paris, France

5:40  38  TREATMENT OF CHILDHOOD HODGKIN'S DISEASE STAGE I AND II WITHOUT RADIOTHERAPY. H. Behrendt, et al, Amsterdam, The Netherlands

5:50  39  SELECTIVE SPLENECTOMY IN CHILDREN WITH HODGKIN'S DISEASE: PROSPECTIVE USE OF A NEW INTRAOPERATIVE STRATEGY IN 109 CHILDREN. S. Strauch, et al, Münster, West-Germany
Thursday, June 14, 1984
2:00 - 6:00 p.m.

Session 7 - WORKSHOP ON ENZYMATIC PATHWAYS IN NORMAL
AND PATHOLOGICAL LYMPHOID CELLS (Room C)
Chairmen: G. Losa and J.-C. Mani

2:00 p.m. 40 ENZYMES INVOLVED IN ADENOSINE METABOLISM, IN
NORMAL OR LEUKEMIC LYMPHOCYTES. J.C. Mani,
Montpellier, France

2:25 41 PURINE NUCLEOTIDE METABOLISM IN NORMAL AND PATHO-
LOGICAL LYMPHOID CELL DIFFERENTIATION.
H.J. Schuurman, Utrecht, The Netherlands

2:50 42 EXPRESSION OF AN ECTOENZYME-CASCADE ON HUMAN
LEUKEMIC AND LYMPHOBLASTOID CELLS. BIOCHEMICAL
AND IMMUNOLOGICAL STUDIES AND CLINICAL SIGNIFICANCE.
W. Gutensohn, München, West-Germany

3:15 DISCUSSION

3:50 43 ENZYMATIC AND ULTRASTRUCTURAL PROPERTIES OF THE
PLASMA MEMBRANE IN HUMAN LEUKEMIAS, NON-HODGKIN'S
LYMPHOMAS AND IN HUMAN LYMPHOBLASTOID CELLS.
G.A. Losa, Locarno, Switzerland

4:15 44 ENZYME PATHWAYS IN MALIGNANT LYMPHOMAS. A.V. Hoffbrand,
London, England

4:40 DISCUSSION

4:50 45 LYMPHOCYTE UROPORPHYRINOGEN SYNTHASE ACTIVITY IN
LYMPHOPROLIFERATIVE DISORDERS - A VALUABLE DIAGNOSTIC
TEST. M. Lahav, et al, Petah Tiqva, Israel

5:05 46 BIOCHEMICAL MARKERS IN NON-HODGKIN'S LYMPHOMA
STAGES III AND IV AND PROGNOSIS - A MULTIVARIATE
ANALYSIS. H. Hagberg, et al, Uppsala, Sweden

5:20 47 PURINE DEGRADATIVE ENZYMES IN THE MALIGNANT CELLS
OF PATIENTS WITH B-CELL LEUKEMIA. A.D. Ho, et al,
Heidelberg, West-Germany

5:35 48 TRANSFERRIN RECEPTOR EXPRESSION IN NON HODGKIN
LYMPHOMAS (NHL). AN IMMUNOHISTOCHEMICAL STUDY.
M. Gobbi, et al, Bologna, Italy

5:50 DISCUSSION
Session 8 - WORKSHOP ON CYTOGENETICS OF HUMAN MALIGNANT LYMPHOMA (Room B)
Chairperson: C.D. Bloomfield

7:30 p.m.  49  Banded chromosome abnormalities in non-Burkitt's, non-Hodgkin's lymphoma. Correlations with morphology and immunologic phenotype. C.D. Bloomfield, Minneapolis, USA

8:00  50  Chromosomal aberrations in low-grade malignant B-cell lymphoproliferative neoplasias. G. Gahrton, Huddinge, Sweden

8:30  51  Chromosome abnormalities and genes in Burkitt's lymphoma. A. De La Chapelle, Helsinki, Finland

9:00  52  TLYM-1, a stage specific transforming gene from T cell lymphomas. M.A. Lane, Boston, USA

9:30  DISCUSSION

Continuation Session 5
HODGKIN'S DISEASE IN ADULTS (Room A)
Chairmen: R.C. Young and H.P. Honegger

7:30 - 9:30 p.m.

7:30 p.m.  53  Prognostic groups for management of clinical stage (C.S.) I and II Hodgkin's disease (H.D.) by radiation therapy. S.B. Sutcliffe, et al, Toronto, Canada

7:45  54  Chemotherapy and localized irradiation in the management of clinical stages I A and II A Hodgkin's disease. F. Teillet, et al, Colombes, France

8:00  55  MOPP vs radiotherapy/MOPP for early-stage Hodgkin's disease (HD) - A six year follow-up. P. O'Dwyer, et al, Bethesda, USA

8:15  56  Randomized study of chemotherapy alone vs. chemotherapy plus radiotherapy in clinical stage IA-II A. S. Pavlovsky, et al, Buenos Aires, Argentina

Thursday, June 14, 1984
7:30 - 9:30 p.m. (continued)

8:45  58  COMBINED MODALITY TREATMENT OF HODGKIN'S DISEASE CONFINED TO LYMPHNODES. J.P. Dutcher, Bronx, USA

9:00  59  CHEMOTHERAPY ALONE VS. COMBINED MODALITY THERAPY FOR STAGE III HODGKIN'S DISEASE: A FIVE-YEAR FOLLOW-UP OF SOUTHWEST ONCOLOGY GROUP (SWOG) STUDY 7518. P.N. Grozea, et al, Oklahoma City, USA

9:15  60  A STUDY OF CHEMOTHERAPY (MVP) FOR PATIENTS WITH STAGES III B AND IV HODGKIN'S DISEASE (HD) WITH AN ASSESSMENT OF PROGNOSTIC FACTORS. W.P. Steward, et al, Manchester, England

FRIDAY, June 15, 1984
8:00 - 10:00 a.m.  POSTER SESSION (Villa Ciani)

Session 9 - SPECIAL FEATURES OF MALIGNANT LYMPHOMA (Room A)
Chairmen: S.A. Rosenberg and R.I. Fisher

10:00 - 12:00 a.m.

10:00 a.m.  61  STAGING AND TREATMENT WITH CYCLOPHOSPHAMIDE, VINCRIStINE AND PREDNISONE (CVP) IN ADVANCED CUTANEOUS T-CELL LYMPHOMAS (CTCL). U. Tirelli, et al, Pordenone, Italy

10:15  62  TREATMENT OF CUTANEOUS T-CELL LYMPHOMAS (CTCL) WITH BIOLOGIC RESPONSE MODIFIERS: RECOMBINANT LEUKOCYTE A INTERFERON (IFL-rA) AND T101 MONOCLONAL ANTIBODY. P.A. Bunn, et al, Bethesda, USA

10:30  63  ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS): BASIC FINDINGS. D. Longo, Bethesda, USA

10:50  64  MALIGNANT LYMPHOMA IN HOMOSEXUAL MEN: CLINICAL FEATURES AND RELATIONSHIP TO ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS). F.M. Muggia, New York, USA

11:10  65  DIFFUSE LYMPHOMAS IN PATIENTS (PTS) AT HIGH RISK FOR ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS). T. Ahmed, et al, Valhalla, USA
Friday, June 15, 1984
10:00 - 12:00 a.m. (continued)

11:20 15  SPECIFIC CYTOTOXIC T-CELLS IN HTLV. R.C. Gallo,
Bethesda, USA

12:00  LUNCH (Room B)

Session 10 - NON HODGKIN LYMPHOMA:
OVERVIEW (Room A)
Chairman: G. Bonadonna

1:45 - 3:20 p.m.
1:45 p.m.  67  OVERVIEW ON CURRENT STRATEGY OF THE TREATMENT OF
NON-HODGKIN'S LYMPHOMAS. J.E. Ultmann, Chicago, USA

2:05 68  UPDATE OF FAVORABLE (LOW GRADE) NON HODGKIN'S
LYMPHOMA. S.A. Rosenberg, Stanford, USA

2:20 69  WATCH AND WAIT VERSUS AGGRESSIVE COMBINED MODALITY
THERAPY FOR ADVANCED FAVORABLE PROGNOSIS NON-HODGKIN'S
LYMPHOMAS. D. Longo, Bethesda, USA

2:35 70  TREATMENT OF DIFFUSE LARGE CELL NON HODGKIN LYMPHOMA.
R.I. Fisher, Bethesda, USA

2:55 71  THE USE OF CHEMOTHERAPY FOR LOCALIZED LARGE CELL
LYMPHOMA; UPDATED RESULTS FROM THE UNIVERSITY OF
ARIZONA. S.E. Jones, Tucson, USA

3:10  DISCUSSION

3:20  INTERMISSION

Session 11 - PATHOLOGY (Room B)
Chairmen: H. Rappaport and F. Rilke

3:30 - 6:00 p.m.
3:30 p.m.  72  CELL OF ORIGIN OF HODGKIN'S DISEASE. C.W. Berard,
Memphis, USA

4:00 73  REACTIVE LYMPHADENOPATHY SIMULATING MALIGNANT LYMPHOMA.
R.F. Dorfman, Stanford, USA
Friday, June 15, 1984
3:30 - 6:00 p.m. (continued)

4:30  74  LYMPHOCYTE DEPLETED HODGKIN'S DISEASE - DOES IT EXIST? E.S. Jaffe, Bethesda, USA

4:45  75  IMMUNO-ELECTRON MICROSCOPIC STUDY OF IMMUNOGLOBULIN PRODUCTION BY NON-HODGKIN'S MALIGNANT LYMPHOMAS. L. Lombardi, Milan, Italy

5:00  76  FLOW-CYTOFLUOROMETRIC DNA ANALYSIS IN NON-HODGKIN'S LYMPHOMAS. B. Christensson, et al, Stockholm, Sweden


5:30  78  BURKITT'S LYMPHOMAS: MORPHOMETRIC ANALYSIS OF 55 CELL LINES WITH GEOGRAPHICAL, VIRAL, IMMUNOLOGIC, AND CYTOGENETIC CORRELATIONS. P. Felman, et al, Pierre-Benite, France

5:45  79  NON-HODGKIN LYMPHOMA WITH MULTILOBATED NUCLEI; A DISTINCT PATHOLOGIC ENTITY? Ph.M. Kluin, et al, Utrecht, The Netherlands

Session 12 - TREATMENT OF NON-HODGKIN LYMPHOMA IN ADULTS (Room A)
Chairmen: J.E. Ultmann and K.W. Brunner

3:30 - 5:45 p.m.

3:30 p.m.  80  TREATMENT OF AGGRESSIVE LYMPHOMA IN JAPAN. M. Ogawa, Tokyo, Japan

3:45  81  MODERATE DOSE METHOTREXATE (m) COMBINED WITH BLEOMYCIN (B), ADRIAMYCIN (A), CYCLOPHOSPHAMIDE (C), ONCOVIN (O) AND DEXAMETHASONE (D), m-BACOD, IN ADVANCED DIFFUSE HISTIOCYTIC LYMPHOMA (DHL). A.T. Skarin, et al, Boston, USA

4:00  82  A RANDOMISED COMPARISON OF ADJUVANT VAP + M VS CMOPP IN RADIOTHERAPY TREATED CLINICAL STAGES I & II HIGH GRADE LYMPHOMA (NHL). J. Wagstaff, et al, Manchester, England
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:30</td>
<td>LYMPHOBLASTIC LYMPHOMA IN ADULTS: A STUDY ON 30 PATIENTS TREATED WITH TWO DIFFERENT PROGRAMS ACCORDING TO BONE MARROW FINDINGS. C. Bernasconi, et al, Pavia, Italy</td>
</tr>
<tr>
<td>4:45</td>
<td>RESULTS OF IFOSFAMIDE - VP-16 SALVAGE COMBINATIONS FOR PATIENTS WITH RECURRENT OR REFRACTORY AGGRESSIVE LYMPHOMA. F. Cabanillas, et al, Houston, USA</td>
</tr>
<tr>
<td>5:00</td>
<td>METHOTREXATE PLUS HIGH DOSE CYTARABINE IN ADVANCED REFRACTORY LYMPHOMA. R.W. Opfell, et al, New York, USA</td>
</tr>
<tr>
<td>5:20</td>
<td>CLINICAL INTERFERON (IFN) STUDIES IN LEUKAEMIA AND LYMPHOMA. T.A. Lister, London, England</td>
</tr>
<tr>
<td>5:30</td>
<td>NEW DRUGS IN THE TREATMENT OF MALIGNANT LYMPHOMA. M. Rozenweig, Syracuse, USA</td>
</tr>
</tbody>
</table>

**SATURDAY, June 16, 1984**
8:30 - 10:45 a.m.

**Session 13 - BONE MARROW TRANSPLANTATION IN NON HODGKIN LYMPHOMA (Room A)**
Chairmen: G.P. Canellos and H.P. Wagner

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 a.m.</td>
<td>SELF-RECOGNITION MECHANISM AND IMMUNE REACTIVITY IN H-2 INCOMPATIBLE BONE MARROW RADIATION CHIMERAS. G.J.M. Mastroni, et al, Locarno, Switzerland</td>
</tr>
<tr>
<td>8:45</td>
<td>APPLICATION OF IMMUNOTOXINS TO AUTOLOGOUS BONE MARROW TRANSPLANTATION. F. Uckun, et al, Istanbul, Turkey</td>
</tr>
</tbody>
</table>
9:00  92  IN VITRO PURGING WITH HYDROPEROXYCYCLOPHOSPHAMIDE (4-HC) AND ITS EFFECTS ON HEMATOPOIETIC AND STROMAL ELEMENTS OF HUMAN BONE MARROW. S. Siena, et al, New York, USA

9:15  93  INDICATION FOR BONE MARROW HARVESTING AND PURGING IN BURKITT LYMPHOMA: A 3 YEARS EXPERIENCE. I. Philip, et al, Lyon, France

9:30  94  AUTOLOGOUS BONE MARROW TRANSPLANTATION FOR RELAPSED NON-HODGKIN'S LYMPHOMA (NHL): ANTI-B, MONOCLONAL ANTIBODY TREATED AUTOLOGOUS BONE MARROW. L. Nadler, et al, Boston, USA

9:45  95  AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR POOR PROGNOSIS LYMPHOMA. S. Gulati, et al, New York, USA

10:00 96  MASSIVE THERAPY AND AUTOLOGOUS BONE MARROW TRANSPLANTATION AS RESCUE PROTOCOL FOR BURKITT LYMPHOMA (EXPERIENCE OF 18 CASES). P. Biron, et al, Lyon, France

10:10 97  TREATMENT OF REFRACTORY NON-HODGKIN'S LYMPHOMA WITH INTENSIVE CHEMORADIOThERAPY AND AUTOLOGOUS BONE MARROW TRANSPLANTATION. G.W. Santos, Baltimore, USA

10:30  DISCUSSION

Session 14 - NON HODGKIN LYMPHOMA:
CLINICAL-PATHOLOGICAL CORRELATIONS (Room B)
Chairmen: C.W. Berard and D. Longo

8:30 - 10:45 a.m.

8:30 a.m. 98  LYMPHOPROLIFERATIVE DISEASES WITH MONOCLONAL GAMMONPATHY. C.W. Berard, Memphis, USA

9:00 99  ANGIOIMMUNOBLASTIC LYMPHADENOPATHY: CLINICAL COURSE, IMMUNOLOGICAL CHARACTERISTICS AND TREATMENT RESULTS IN 25 PATIENTS. R. v. Roemeling, et al, Hannover, West-Germany
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:15</td>
<td>100</td>
<td>A Continuum of all and NHL types according to the differentiation steps determined by monoclonal antibodies. Correlation with WHO, FAB and NCI classifications. G. Mathe, et al, Villejuif, France</td>
</tr>
<tr>
<td>09:30</td>
<td>101</td>
<td>Comparison of the working formulation (WF) of non-Hodgkin's lymphoma (NHL) with the Rappaport (R), Kiel (K), and Lukes &amp; Collins (L&amp;C) classifications. Terminological correlations and prognostic value. J. Ersbøll, et al, Copenhagen, Denmark</td>
</tr>
<tr>
<td>09:45</td>
<td>102</td>
<td>Clinical and prognostic relevance of the Kiel classification on non-Hodgkin lymphomas (NHL): Results of a prospective multicenter study. G. Brittinger, et al, Essen, West-Germany</td>
</tr>
<tr>
<td>10:00</td>
<td>103</td>
<td>Bone marrow and blood involvement by non-Hodgkin's lymphoma: clinicopathologic features and prognostic significance in relationship to the working formulation. E. Morra, et al, Pavia, Italy</td>
</tr>
<tr>
<td>10:30</td>
<td>105</td>
<td>Primary intestinal lymphoma of adults in the middle East - comparative study of IPSID vs. non-IPSID. P.A. Salem, et al, Beirut, Lebanon</td>
</tr>
<tr>
<td>10:45</td>
<td></td>
<td>Intermission</td>
</tr>
<tr>
<td>11:00</td>
<td>106</td>
<td>Henry Kaplan Memorial Lecture (Room A)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The importance of viruses in lymphoma. R.C. Gallo, Bethesda, USA</td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td>Adjourn</td>
</tr>
</tbody>
</table>
40% REMISSION (UICC-KRITERIEN) BEI UNSELEKTIONIERTEM PATIENTINNEN MIT HOCHDOSIERTER GESTAGENTHERAPIE

**Farlutal®**

500 mg / 1000 mg i.m. oral auch als Trinkpulver verwendbar

Ø 100 mg / 200 mg / 250 mg KASSENZULASSIG

LNEU

**WIRKSAM AUCH NACH VERSAGEN EINER CHEMOTHERAPIE ODER Anderer Hormontherapie □ POST- UND MENOPAUSAL WIRKSAM □ LINDERUNG DER BESCHWERDEN □ ORAL UND INTRAMUSKULAR □ NIEDRIGE NEBENWIRKUNGSRATE**

**VERBESSERUNG DER LEBENSQUALITÄT**

**INDIKATIONEN:** METASTASIERENDES MAMMAKARZINOM □ ENDOMETRIUMKARZINOM □ PROSTATAKARZINOM □ HYPERNEPHROM

**WEITERE INFORMATION ÜBER KONTRAINDIKATION UND NEBENWIRKUNGEN SIEHE ARZNEIMITTEL-KOMPENDIUM ODER PACKLINGSPROSPEKT**

MONTEDISON GROUP

FARMITALIA CARLO ERBA
Rabdentalsrasse 83 · Postfach 316 · 3000 Bern 25 · Tel. (031) 42 2311/12